Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
Are there pediatric pharmacokinetic studies for Abasaglar® (insulin glargine)?
Eli Lilly and Company has no pharmacokinetic data of Abasaglar in pediatric patients. An independent study evaluated pharmacokinetics of insulin glargine in children.
Results from PK study with Insulin Glargine
Plasma trough concentrations of insulin glargine and its main 21A-Gly-human insulin (M1) and 21A-Gly-des-30B-Thr-human insulin (M2) metabolites
1Danne T, Becker RHA, Ping L, Philotheou A. Insulin glargine metabolite 21A-Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Pediatr Diabetes. 2015;16(4):299-304. https://doi.org/10.1111/pedi.12161
2Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35(12):2626-2630. https://doi.org/10.2337/dc12-0270
Date of Last Review: April 13, 2021